Open Payments

Karmanos Cancer Hospital

Type
Teaching hospital
Where
Detroit, MI
Medicare CCN
230297
Received
$10,706,325 in 1,836 records, 2021 ($32,500 general, $10,673,825 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2021General payment5$32,500
2021Research payment1,831$10,673,825

By company

CompanyRecordsAmountYears
Merck Sharp & Dohme LLC67$2,246,4562021
Alkermes, Inc.207$1,900,0662021
Janssen Research & Development, LLC216$704,5162021
Pharmacyclics LLC, an AbbVie Company79$666,5042021
Regeneron Pharmaceuticals, Inc.121$609,7702021
SEAGEN INC.121$502,9292021
Takeda Pharmaceuticals U.S.A., Inc.108$394,4292021
BIOVERATIV THERAPEUTICS INC.82$302,1972021
Genentech, Inc.104$249,0262021
PFIZER INC.48$247,5322021
AstraZeneca Pharmaceuticals LP17$243,5942021
Daiichi Sankyo Inc.63$241,8812021
Gilead Sciences, Inc.49$222,2772021
E.R. Squibb & Sons, L.L.C.18$221,6732021
Karyopharm Therapeutics Inc.5$202,9702021
Celgene Corporation8$172,9732021
Novartis Pharmaceuticals Corporation5$150,1042021
SERVIER PHARMACEUTICALS LLC5$141,5712021
Incyte Corporation130$127,3742021
Boehringer Ingelheim Pharmaceuticals, Inc.2$114,3052021
ABBVIE INC.21$108,5842021
Exelixis Inc.40$89,3272021
Clovis Oncology, Inc.18$82,4092021
Corcept Therapeutics37$82,4062021
Blue Earth Diagnostics14$78,2942021
Radius Health, Inc.18$69,8082021
Boehringer Ingelheim International GmbH17$69,1142021
Bayer Healthcare Pharmaceuticals Inc.21$54,0952021
BeiGene, Ltd.20$50,0142021
Kite Pharma, Inc.30$45,9182021
Novocure Inc.32$45,4582021
Theratechnologies Inc.7$44,9922021
GlaxoSmithKline, LLC.8$37,3872021
AstraZeneca UK Limited4$36,9602021
Eisai Inc.47$30,8602021
Eli Lilly and Company4$23,4772021
CSL Behring2$21,3952021
Daiichi Sankyo Company LTD3$13,3802021
TAIHO ONCOLOGY, INC.9$10,0662021
TRILLIUM THERAPEUTICS USA, LLC7$10,0662021
Ipsen Biopharmaceuticals, Inc2$7,9692021
Ipsen Bioscience Inc.3$7,0002021
Astellas Pharma Global Development7$6,0602021
Dova Pharmaceuticals1$5,0002021
Adaptive Biotechnologies Corporation1$5,0002021
QED Therapeutics, Inc.5$3,6252021
EMD Serono, Inc.1$2,0002021
HOLOGIC INC1$1,7502021
Boston Scientific Corporation1$1,7482021

By nature of payment

NatureRecordsAmount
Research payment1,831$10,673,825
Space rental or facility fees (teaching hospital only)2$12,500
Charitable Contribution1$10,000
Grant2$10,000

Records

DateCompanyAmountNatureFormProductStudyYear
2021-12-31Merck Sharp & Dohme LLC$552,500Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAn Open-label Phase 1b,2a Study of NT-I7 Hyleukin-7 in Combination with Pembrolizumab in Subjects with Relapsed,Refracto2021
2021-12-31Merck Sharp & Dohme LLC$138,749Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrol2021
2021-12-31Merck Sharp & Dohme LLC$130,964Research paymentIn-kind items and services Drug, ONCOLOGYPhase I Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumor2021
2021-12-31Merck Sharp & Dohme LLC$130,299Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu2021
2021-12-31Merck Sharp & Dohme LLC$86,306Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini2021
2021-12-31Merck Sharp & Dohme LLC$52,313Research paymentIn-kind items and services Drug, ONCOLOGYPhase I Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumor2021
2021-12-31Merck Sharp & Dohme LLC$44,335Research paymentIn-kind items and services Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu2021
2021-12-31Merck Sharp & Dohme LLC$43,568Research paymentIn-kind items and services Biological, ONCOLOGYA Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chemotherapy or Lenvatin2021
2021-12-31Merck Sharp & Dohme LLC$39,090Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r2021
2021-12-31Merck Sharp & Dohme LLC$38,773Research paymentIn-kind items and services Biological, ONCOLOGYA Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab MK-7684 with Pembrolizumab M2021
2021-12-31Merck Sharp & Dohme LLC$32,569Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand2021
2021-12-31Merck Sharp & Dohme LLC$29,129Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with2021
2021-12-31Merck Sharp & Dohme LLC$27,000Research paymentIn-kind items and services Biological, ONCOLOGYA Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chemotherapy or Lenvatin2021
2021-12-31Merck Sharp & Dohme LLC$26,546Research paymentIn-kind items and services Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrol2021
2021-12-31Merck Sharp & Dohme LLC$22,728Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792021
2021-12-31Merck Sharp & Dohme LLC$20,305Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792021
2021-12-31Merck Sharp & Dohme LLC$17,351Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini2021
2021-12-31Merck Sharp & Dohme LLC$15,696Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with2021
2021-12-31Merck Sharp & Dohme LLC$15,680Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally A2021
2021-12-31Merck Sharp & Dohme LLC$15,176Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r2021
2021-12-31Merck Sharp & Dohme LLC$13,055Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAn Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly2021
2021-12-31Merck Sharp & Dohme LLC$12,755Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand2021
2021-12-31Merck Sharp & Dohme LLC$10,801Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma2021
2021-12-31Merck Sharp & Dohme LLC$6,742Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III Study of Pembrolizumab MK-3475 vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously S2021
2021-12-31Merck Sharp & Dohme LLC$6,599Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv2021
2021-12-31AstraZeneca Pharmaceuticals LP$5,229Research paymentIn-kind items and servicesA Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) i2021
2021-12-31Merck Sharp & Dohme LLC$5,154Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized Double-Blind, Phase III Study of PlatinumPemtrexed Chemotherapy with or without Pembrolizumab MK-3475 in Fi2021
2021-12-31Merck Sharp & Dohme LLC$4,813Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAn Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly2021
2021-12-31Merck Sharp & Dohme LLC$4,359Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the 2021
2021-12-31Merck Sharp & Dohme LLC$3,982Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus 2021
2021-12-31Merck Sharp & Dohme LLC$3,066Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Clinical Trial of Pembrolizumab MK-3475 in First Line Treatment of Recurrent,Metastatic Head and Neck Squamous2021
2021-12-31Merck Sharp & Dohme LLC$2,785Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refracto2021
2021-12-31Merck Sharp & Dohme LLC$2,779Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg2021
2021-12-31Merck Sharp & Dohme LLC$2,087Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase II Trial of Pembrolizumab MK-3475 in Subjects with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-12021
2021-12-31Merck Sharp & Dohme LLC$1,962Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for 2021
2021-12-31AstraZeneca Pharmaceuticals LP$1,550Research paymentIn-kind items and servicesIMFINZI Biological, OncologyA Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co2021
2021-12-31Merck Sharp & Dohme LLC$1,355Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma2021
2021-12-31Merck Sharp & Dohme LLC$1,183Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-Label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with R2021
2021-12-31Merck Sharp & Dohme LLC$628Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase 1,2a Study of Double-Immune Suppression Blockade by Combining a CSF1R Inhibitor PLX3397 with an Anti-PD-1 Antibody2021
2021-12-31Merck Sharp & Dohme LLC$608Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase Ib Trial of Pembrolizumab MK-3475 in Combination with Dinaciclib MK-7965 in Subjects with Hematologic Malignancies2021
2021-12-31AstraZeneca Pharmaceuticals LP$158Research paymentIn-kind items and servicesIMFINZI Biological, OncologyA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio2021
2021-12-31AstraZeneca Pharmaceuticals LP$96Research paymentIn-kind items and servicesStudy of MEDI4736 Durvalumab With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer2021
2021-12-31Merck Sharp & Dohme LLC$75Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Met2021
2021-12-31Merck Sharp & Dohme LLC$31Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Recurrent Ovari2021
2021-12-31Merck Sharp & Dohme LLC$1Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with 2021
2021-12-30Pharmacyclics LLC, an AbbVie Company$46,127Research paymentCash or cash equivalentIMBRUVICA Drug, ONCOLOGYA phase II multicenter single arm study to evaluate the efficacy and safety of single agent Brutons tyrosine kinase inhi2021
2021-12-30Novocure Inc.$1,000Research paymentCash or cash equivalentEF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and2021
2021-12-30Novocure Inc.$1,000Research paymentCash or cash equivalentEF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and2021
2021-12-29Merck Sharp & Dohme LLC$89,409Research paymentCash or cash equivalent Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu2021
2021-12-29Gilead Sciences, Inc.$20,800Research paymentCash or cash equivalentA Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma2021
2021-12-29Merck Sharp & Dohme LLC$5,740Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase III Study of Pembrolizumab MK-3475 vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously S2021
2021-12-29Boehringer Ingelheim International GmbH$4,880Research paymentCash or cash equivalentBI 754091 first-in-man dose escalation2021
2021-12-28TRILLIUM THERAPEUTICS USA, LLC$2,310Research paymentCash or cash equivalentA PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L2021
2021-12-28TRILLIUM THERAPEUTICS USA, LLC$1,500Research paymentCash or cash equivalentA PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L2021
2021-12-28Daiichi Sankyo Inc.$1,500Research paymentCash or cash equivalentEnhertu Drug, ONCOLOGYDS-8201-A-U2042021
2021-12-28TRILLIUM THERAPEUTICS USA, LLC$1,422Research paymentCash or cash equivalentA PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L2021
2021-12-28TRILLIUM THERAPEUTICS USA, LLC$1,422Research paymentCash or cash equivalentA PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L2021
2021-12-28TRILLIUM THERAPEUTICS USA, LLC$1,422Research paymentCash or cash equivalentA PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L2021
2021-12-28Daiichi Sankyo Inc.$1,357Research paymentCash or cash equivalentEnhertu Drug, ONCOLOGYDS-8201-A-U2042021
2021-12-28TRILLIUM THERAPEUTICS USA, LLC$1,000Research paymentCash or cash equivalentA PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L2021
2021-12-28TRILLIUM THERAPEUTICS USA, LLC$990Research paymentCash or cash equivalentA PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L2021
2021-12-27Janssen Research & Development, LLC$1,108Research paymentCash or cash equivalentA Phase 1b2 Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Sub2021
2021-12-27Takeda Pharmaceuticals U.S.A., Inc.$1,016Research paymentCash or cash equivalentA STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR2021
2021-12-27Janssen Research & Development, LLC$838Research paymentCash or cash equivalentA Phase 1b2 Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Sub2021
2021-12-24Ipsen Bioscience Inc.$2,750Research paymentCash or cash equivalentONIVYDE Drug, OncologyAn Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le2021
2021-12-24Janssen Research & Development, LLC$2,000Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2021
2021-12-23Janssen Research & Development, LLC$488Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2021
2021-12-22Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-22Takeda Pharmaceuticals U.S.A., Inc.$5,331Research paymentCash or cash equivalentA STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR2021
2021-12-22Regeneron Pharmaceuticals, Inc.$3,987Research paymentCash or cash equivalentPhase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN2021
2021-12-22Alkermes, Inc.$3,100Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-22Alkermes, Inc.$3,100Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-22Alkermes, Inc.$2,400Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-22Theratechnologies Inc.$2,200Research paymentCash or cash equivalentA Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients With Advanced Solid Tumors and Expansion in Patients 2021
2021-12-22Alkermes, Inc.$1,676Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-22Takeda Pharmaceuticals U.S.A., Inc.$1,500Research paymentCash or cash equivalentALUNBRIG Drug, ONCOLOGYBRIGATINIB IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+), ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PROG2021
2021-12-22Regeneron Pharmaceuticals, Inc.$1,376Research paymentCash or cash equivalentPhase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN2021
2021-12-22PFIZER INC.$1,000Research paymentCash or cash equivalentLORBRENA Drug, ONCOLOGYPHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HA2021
2021-12-22PFIZER INC.$990Research paymentCash or cash equivalentLORBRENA Drug, ONCOLOGYPHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HA2021
2021-12-22PFIZER INC.$528Research paymentCash or cash equivalentLORBRENA Drug, ONCOLOGYPHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HA2021
2021-12-22Incyte Corporation$200Research paymentCash or cash equivalentA Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due t2021
2021-12-22Alkermes, Inc.$79Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-21Pharmacyclics LLC, an AbbVie Company$59,680Research paymentIn-kind items and servicesIMBRUVICA Drug, ONCOLOGYA phase II multicenter single arm study to evaluate the efficacy and safety of single agent Brutons tyrosine kinase inhi2021
2021-12-21Daiichi Sankyo Inc.$3,068Research paymentCash or cash equivalentTuralio Drug, ONCOLOGYPL3397-A-U1262021
2021-12-21Daiichi Sankyo Inc.$2,666Research paymentCash or cash equivalentTuralio Drug, ONCOLOGYPL3397-A-U1262021
2021-12-21Daiichi Sankyo Inc.$696Research paymentCash or cash equivalentTuralio Drug, ONCOLOGYPL3397-A-U1262021
2021-12-21Daiichi Sankyo Inc.$696Research paymentCash or cash equivalentTuralio Drug, ONCOLOGYPL3397-A-U1262021
2021-12-21Daiichi Sankyo Inc.$696Research paymentCash or cash equivalentTuralio Drug, ONCOLOGYPL3397-A-U1262021
2021-12-21Daiichi Sankyo Inc.$696Research paymentCash or cash equivalentTuralio Drug, ONCOLOGYPL3397-A-U1262021
2021-12-21Daiichi Sankyo Inc.$696Research paymentCash or cash equivalentTuralio Drug, ONCOLOGYPL3397-A-U1262021
2021-12-21Daiichi Sankyo Inc.$696Research paymentCash or cash equivalentTuralio Drug, ONCOLOGYPL3397-A-U1262021
2021-12-20Genentech, Inc.$11,178Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyPH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH22021
2021-12-20Genentech, Inc.$8,539Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyPH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH22021
2021-12-20Genentech, Inc.$5,060Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyPH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH22021
2021-12-20Genentech, Inc.$5,000Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyPH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH22021
2021-12-20Janssen Research & Development, LLC$4,100Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2021
2021-12-20Janssen Research & Development, LLC$1,746Research paymentCash or cash equivalentA Phase 1b2 Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Sub2021
2021-12-20Exelixis Inc.$1,019Research paymentCash or cash equivalentCABOMETYX Drug, OncologyStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors2021
2021-12-20Janssen Research & Development, LLC$398Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2021
2021-12-17Theratechnologies Inc.$5,278Research paymentCash or cash equivalentA Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients With Advanced Solid Tumors and Expansion in Patients 2021
2021-12-17Regeneron Pharmaceuticals, Inc.$3,500Research paymentCash or cash equivalentPhase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN2021
2021-12-17Janssen Research & Development, LLC$2,204Research paymentCash or cash equivalentA Phase 1 First In Human Dose Escalation Study of JNJ67571244 bispecific antibody targeting CD33 and CD3 in Subjects wit2021
2021-12-17Regeneron Pharmaceuticals, Inc.$2,000Research paymentCash or cash equivalentPhase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN2021
2021-12-17Janssen Research & Development, LLC$1,500Research paymentCash or cash equivalentA Phase 1 First In Human Dose Escalation Study of JNJ67571244 bispecific antibody targeting CD33 and CD3 in Subjects wit2021
2021-12-17Janssen Research & Development, LLC$1,320Research paymentCash or cash equivalentA Phase 1 First In Human Dose Escalation Study of JNJ67571244 bispecific antibody targeting CD33 and CD3 in Subjects wit2021
2021-12-17Regeneron Pharmaceuticals, Inc.$816Research paymentCash or cash equivalentPhase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN2021
2021-12-17Janssen Research & Development, LLC$200Research paymentCash or cash equivalentA Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub2021
2021-12-17Corcept Therapeutics$200Research paymentCash or cash equivalentCORT125134-5532021
2021-12-17Janssen Research & Development, LLC$70Research paymentCash or cash equivalentA Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub2021
2021-12-16Alkermes, Inc.$16,310Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-16Alkermes, Inc.$15,787Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-16Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-16Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-16Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-16Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-16Janssen Research & Development, LLC$8,363Research paymentCash or cash equivalentA Phase 1 First In Human Dose Escalation Study of JNJ67571244 bispecific antibody targeting CD33 and CD3 in Subjects wit2021
2021-12-16Daiichi Sankyo Inc.$6,247Research paymentCash or cash equivalentEnhertu Drug, ONCOLOGYDS-8201-A-U2042021
2021-12-16Janssen Research & Development, LLC$2,271Research paymentCash or cash equivalentAn Open label Multi Center Phase 1b Study of JNJ74494550 Cusatuzumab; AntiCD70 Monoclonal Antibody in Combination with B2021
2021-12-16Karyopharm Therapeutics Inc.$2,000Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Multicenter, Phase 1/2 Study of Selinexor in Combination with Backbone Treatments or Novel Therapies in Patients with 2021
2021-12-16Janssen Research & Development, LLC$2,000Research paymentCash or cash equivalentAn Open label Multi Center Phase 1b Study of JNJ74494550 Cusatuzumab; AntiCD70 Monoclonal Antibody in Combination with B2021
2021-12-16Alkermes, Inc.$1,500Research paymentCash or cash equivalentA Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i2021
2021-12-16Regeneron Pharmaceuticals, Inc.$1,500Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2021
2021-12-16Janssen Research & Development, LLC$1,360Research paymentCash or cash equivalentAn Open label Multi Center Phase 1b Study of JNJ74494550 Cusatuzumab; AntiCD70 Monoclonal Antibody in Combination with B2021
2021-12-16Regeneron Pharmaceuticals, Inc.$1,320Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2021
2021-12-16Alkermes, Inc.$1,320Research paymentCash or cash equivalentA Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i2021
2021-12-16Novocure Inc.$1,075Research paymentCash or cash equivalentEF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi2021
2021-12-16Alkermes, Inc.$1,000Research paymentCash or cash equivalentA Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i2021
2021-12-16Novocure Inc.$1,000Research paymentCash or cash equivalentEF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi2021
2021-12-16Regeneron Pharmaceuticals, Inc.$1,000Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2021
2021-12-16Regeneron Pharmaceuticals, Inc.$792Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2021
2021-12-16Janssen Research & Development, LLC$500Research paymentCash or cash equivalentBiomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer2021
2021-12-16Alkermes, Inc.$385Research paymentIn-kind items and servicesA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-16Alkermes, Inc.$123Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-16Alkermes, Inc.$68Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-15Merck Sharp & Dohme LLC$53,281Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini2021
2021-12-15Merck Sharp & Dohme LLC$23,566Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally A2021
2021-12-15BeiGene, Ltd.$6,800Research paymentCash or cash equivalentA Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Ho2021
2021-12-15Takeda Pharmaceuticals U.S.A., Inc.$420Research paymentCash or cash equivalentA STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR2021
2021-12-15Takeda Pharmaceuticals U.S.A., Inc.$360Research paymentCash or cash equivalentA STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR2021
2021-12-15Takeda Pharmaceuticals U.S.A., Inc.$240Research paymentCash or cash equivalentA STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR2021
2021-12-15SEAGEN INC.$100Research paymentCash or cash equivalentA Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies2021
2021-12-15Takeda Pharmaceuticals U.S.A., Inc.$60Research paymentCash or cash equivalentA STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR2021
2021-12-14PFIZER INC.$2,310Research paymentCash or cash equivalentBAVENCIO Drug, ONCOLOGYA PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB002021
2021-12-14PFIZER INC.$1,500Research paymentCash or cash equivalentBAVENCIO Drug, ONCOLOGYA PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB002021
2021-12-14PFIZER INC.$660Research paymentCash or cash equivalentBAVENCIO Drug, ONCOLOGYA PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB002021
2021-12-13Janssen Research & Development, LLC$11,436Research paymentCash or cash equivalentA Phase 1 First In Human Dose Escalation Study of JNJ67571244 bispecific antibody targeting CD33 and CD3 in Subjects wit2021
2021-12-13Janssen Research & Development, LLC$2,271Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2021
2021-12-13Janssen Research & Development, LLC$2,000Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2021
2021-12-13Janssen Research & Development, LLC$92Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2021
2021-12-10AstraZeneca Pharmaceuticals LP$2,000Research paymentCash or cash equivalentIMFINZI Biological, OncologyA Randomized Double-blind Placebo-controlled Phase III Study of Neoadjuvant Adjuvant Durvalumab and FLOT Chemotherapy Fo2021
2021-12-10Exelixis Inc.$1,023Research paymentCash or cash equivalentCABOMETYX Drug, OncologyStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors2021
2021-12-10Alkermes, Inc.$378Research paymentIn-kind items and servicesA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-10Alkermes, Inc.$259Research paymentIn-kind items and servicesA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-09Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-09Regeneron Pharmaceuticals, Inc.$9,492Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2021
2021-12-09Genentech, Inc.$4,344Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyPHII PLACEBO CONTROLLED OF TIRAGOLUMAB AND ATEZO IN NSCLC2021
2021-12-09Alkermes, Inc.$3,400Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-09Alkermes, Inc.$3,400Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-09Alkermes, Inc.$3,400Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-09Genentech, Inc.$1,982Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyPHASE I PROTOCOL COMBO FOR MULTIPLE MYELOMA WITH LENALIDOMIDE2021
2021-12-09Daiichi Sankyo Inc.$1,051Research paymentCash or cash equivalentTuralio Drug, ONCOLOGYPL3397-A-U1262021
2021-12-09Regeneron Pharmaceuticals, Inc.$1,000Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2021
2021-12-09Genentech, Inc.$1,000Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyOBINUTUZUMAB GAZYVA POLATUZUMAB VEDOTIN LENALIDOMIDE IN RR FL DLBCL2021
2021-12-09Genentech, Inc.$990Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyOBINUTUZUMAB GAZYVA POLATUZUMAB VEDOTIN LENALIDOMIDE IN RR FL DLBCL2021
2021-12-09Regeneron Pharmaceuticals, Inc.$660Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2021
2021-12-09Regeneron Pharmaceuticals, Inc.$600Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2021
2021-12-09Janssen Research & Development, LLC$200Research paymentCash or cash equivalentA Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub2021
2021-12-09Alkermes, Inc.$80Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-09Janssen Research & Development, LLC$68Research paymentCash or cash equivalentA Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub2021
2021-12-09Alkermes, Inc.$68Research paymentCash or cash equivalentA Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec2021
2021-12-08Regeneron Pharmaceuticals, Inc.$101,055Research paymentCash or cash equivalentPhase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN2021
2021-12-08Regeneron Pharmaceuticals, Inc.$5,440Research paymentCash or cash equivalentPhase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN2021
2021-12-08Regeneron Pharmaceuticals, Inc.$5,440Research paymentCash or cash equivalentPhase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN2021
2021-12-08SEAGEN INC.$4,154Research paymentCash or cash equivalentADCETRIS Biological, OncologyA Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or 2021
2021-12-08SEAGEN INC.$2,000Research paymentCash or cash equivalentA Phase 1 Study of SEA-CD70 in Myeloid Malignancies2021
2021-12-08SEAGEN INC.$2,000Research paymentCash or cash equivalentA Phase 1 Study of SEA-CD70 in Myeloid Malignancies2021
2021-12-08Genentech, Inc.$422Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyNEOADJUVANT NSCLC2021
2021-12-08SEAGEN INC.$231Research paymentCash or cash equivalentTIVDAK Biological, OncologyOpen Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in o2021
2021-12-08Regeneron Pharmaceuticals, Inc.$84Research paymentCash or cash equivalentPhase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN2021
2021-12-08Regeneron Pharmaceuticals, Inc.$84Research paymentCash or cash equivalentPhase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN2021
2021-12-07SEAGEN INC.$10,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentADCETRIS Biological, Oncology2021
2021-12-07Takeda Pharmaceuticals U.S.A., Inc.$1,500Research paymentCash or cash equivalentICLUSIG Drug, ONCOLOGYA RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA T2021
2021-12-07Takeda Pharmaceuticals U.S.A., Inc.$990Research paymentCash or cash equivalentICLUSIG Drug, ONCOLOGYA RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA T2021
2021-12-07Takeda Pharmaceuticals U.S.A., Inc.$660Research paymentCash or cash equivalentICLUSIG Drug, ONCOLOGYA RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA T2021
2021-12-06Pharmacyclics LLC, an AbbVie Company$39,787Research paymentIn-kind items and servicesIMBRUVICA Drug, ONCOLOGYA phase II multicenter single arm study to evaluate the efficacy and safety of single agent Brutons tyrosine kinase inhi2021
2021-12-06Genentech, Inc.$5,000Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyLCMC32021
2021-12-06Janssen Research & Development, LLC$398Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2021
2021-12-03Merck Sharp & Dohme LLC$14,439Research paymentCash or cash equivalent Biological, ONCOLOGYA Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chemotherapy or Lenvatin2021
2021-12-03Takeda Pharmaceuticals U.S.A., Inc.$808Research paymentCash or cash equivalentA RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HO2021
2021-12-02Janssen Research & Development, LLC$7,141Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2021
2021-12-02Ipsen Bioscience Inc.$2,000Research paymentCash or cash equivalentONIVYDE Drug, OncologyAn Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le2021
2021-12-02ABBVIE INC.$369Research paymentCash or cash equivalentVENCLEXTA Drug, ONCOLOGYA Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexa2021
2021-12-01Takeda Pharmaceuticals U.S.A., Inc.$14,553Research paymentCash or cash equivalentA STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR2021
2021-12-01Janssen Research & Development, LLC$4,576Research paymentCash or cash equivalentA Phase 1b2 Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Sub2021
2021-12-01Takeda Pharmaceuticals U.S.A., Inc.$2,145Research paymentCash or cash equivalentA STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR2021
2021-12-01Takeda Pharmaceuticals U.S.A., Inc.$180Research paymentCash or cash equivalentA STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR2021
2021-12-01Takeda Pharmaceuticals U.S.A., Inc.$132Research paymentCash or cash equivalentA STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR2021
2021-12-01Pharmacyclics LLC, an AbbVie Company$80Research paymentCash or cash equivalentIMBRUVICA Drug, ONCOLOGYStudy of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)2021
2021-12-01Pharmacyclics LLC, an AbbVie Company$80Research paymentCash or cash equivalentIMBRUVICA Drug, ONCOLOGYStudy of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)2021
2021-12-01Takeda Pharmaceuticals U.S.A., Inc.$60Research paymentCash or cash equivalentA STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR2021

The latest 200 records of 1,836.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Wayne CountyDetroit city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Detroit, MI, county Wayne County, MI, state Michigan; placed by its city name.

MeasurePlace (city or town)
Detroit, MI
County
Wayne County, MI
State
Michigan
Population B01003638,5301,772,25910,077,761
Population, 2020 census P1639,1111,793,56110,077,331
Median age B0100235.237.940.2
Under 18 B0100124.8%23.6%21.2%
65 and over B0100115.1%16.6%18.6%
Households B11001257,998700,5914,076,369
Foreign born B050026.6%10.3%7.2%
Median household income B19013$39,938$60,539$72,875
Median family income B19113$49,398$79,522$93,357
Per capita income B19301$24,594$34,906$40,735
Poverty rate B1700132.7%20.8%13.2%
Unemployment rate B2302514.0%8.7%5.7%
Civilian labor force B23025268,955828,8385,018,449
Mean commute (minutes) B0801324.824.724.2
Bachelor's degree or higher B1500318.1%27.6%32.4%
Housing units B25001329,393801,0834,622,236
Owner-occupied B2500350.3%64.8%73.2%
Renters B2500349.7%35.2%26.8%
Median home value B25077$83,900$178,500$231,600
Median gross rent B25064$1,074$1,132$1,129
White, not Hispanic B0300210.8%47.9%72.4%
Black B0300275.0%36.6%13.1%
Hispanic or Latino B030028.3%6.9%5.9%
Asian B030021.7%3.7%3.4%
American Indian and Alaska Native B030020.2%0.2%0.3%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Detroit, MI.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.